RG7356

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD44 CD44s Expression1
RG7356	Malignant Neoplasm

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

CD44 CD44v3-v10 + CD44 CD44v8-v101
RG7356	Malignant NeoplasmALIAS	Predictive	B	Supports Resistance	4	submitted	EID9395 In RG7356 xenograft models, cell lines expressing predominantly a mixture of CD44v8-v10 and CD44v3-v10 show no response to treatment with RG7356 measured as a percentage of tumor growth inhibition. In… (full text at CIViC) PMID 25762343 · Birzele et al., 2015 · Open in CIViC	civic